DSM Pharmaceuticals, Inc. has signed a manufacturing agreement with APT Pharmaceuticals, Inc. DSM will produce the commercial drug supply as a sterile product for pulmonary delivery for APT. The agreement will utilize DSM’s commercial facilities in Greenville, NC.

“DSM has a superior reputation in sterile manufacturing, experience with similar drug products, and an excellent working relationship with the FDA,” commented Howard Raff, Ph.D., APT’s chief operating officer, “In addition to their experience, they also have the capability to provide increased scale through commercialization.”

“DSM Pharmaceuticals Inc. is pleased to welcome APT as a client. APT is a specialty drug development company with an outstanding staff that is focused on effective treatments for significant unmet medical needs and we at DSM are proud to be part of those efforts,” stated Terry Novak, president, DSM Pharmaceuticals Inc.